Ensign Peak Advisors, Inc Fate Therapeutics Inc Transaction History

Ensign Peak Advisors, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $115,668 - $160,137	24,300 Added 24.43%	123,750 $589,000
Q1 2023 May 15, 2023	BUY	$4.24 - $11.12 $143,312 - $375,856	33,800 Added 51.49%	99,450 $566,000
Q4 2022 Feb 13, 2023	BUY	$9.86 - $23.83 $447,644 - $1.08 Million	45,400 Added 224.2%	65,650 $662,000
Q4 2021 Feb 11, 2022	BUY	$47.84 - $64.34 $968,760 - $1.3 Million	20,250 New	20,250 $1.19 Million
Q3 2021 Nov 12, 2021	SELL	$59.27 - $95.73 $417,201 - $673,843	-7,039 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$67.25 - $92.52 $879,495 - $1.21 Million	-13,078 Reduced 65.01%	7,039 $611,000
Q1 2021 May 12, 2021	SELL	$72.16 - $117.4 $910,442 - $1.48 Million	-12,617 Reduced 38.54%	20,117 $1.66 Million
Q4 2020 Feb 12, 2021	SELL	$38.09 - $100.95 $616,600 - $1.63 Million	-16,188 Reduced 33.09%	32,734 $2.98 Million
Q3 2020 Nov 12, 2020	BUY	$30.41 - $40.5 $1.33 Million - $1.77 Million	43,740 Added 844.08%	48,922 $1.96 Million
Q1 2020 May 11, 2020	SELL	$17.28 - $31.88 $157,092 - $289,821	-9,091 Reduced 63.69%	5,182 $115,000
Q4 2019 Feb 14, 2020	BUY	$13.39 - $20.73 $191,115 - $295,879	14,273 New	14,273 $279,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $160M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.